Octreotide for the treatment of sulfonylurea poisoning

Clinical Toxicology

Volumn 50, Issue 9, 2012, Pages 795-804

  Glatstein, Miguel ^a,b   Scolnik, Dennis ^c   Bentur, Yedidia ^d  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d Israel Poison Information Center   (Israel)

Author keywords

Hypoglycemia; Octreotide; Poisoning; Sulfonylurea

Indexed keywords

ATENOLOL; CALCIUM; CHLORPROPAMIDE; DIAZOXIDE; G PROTEIN COUPLED RECEPTOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; GLUCOSE; INSULIN; METFORMIN; OCTREOTIDE; SOMATOSTATIN RECEPTOR 2; SULFONYLUREA; TOLBUTAMIDE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; APNEA; CALCIUM TRANSPORT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); CONTINUOUS INFUSION; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INFUSION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; INGESTION; INSULIN RELEASE; INTOXICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; RECURRENT DISEASE; REVIEW; SULFONYLUREA POISONING;

ANIMALS; HUMANS; HYPOGLYCEMIA; OCTREOTIDE; SULFONYLUREA COMPOUNDS;

EID: 84867725786     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2012.734626     Document Type: Review

References (73)

1. Natahn DM, Rousell A, Godine JE. Glyburide or insulin form metabolic control in non-insulin-dependent diabetes mellitus. A randomized, double-blind study. Ann Intern Med 1988; 108 : 334 - 340.
2. H arrigan R A, N athan M S, B eattie P. O ral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment. Ann Emerg Med 2001; 38 : 68 - 78. (Pubitemid 32606034)
3. Abrahamsson H, Berggren PO, Rorsman P. Direct measurement of increased free cytoplasmic Ca2 - in mouse pancreatic beta-cells following stimulation by hypoglycemic sulfonylureas. FEBS Lett 1985; 190 : 21 - 24. (Pubitemid 16251313)
4. Spiller HA. Management of sulfonylurea ingestion. Pediat Emerg Care 1999; 15 : 227 - 230.
5. B osse G M. A ntidiabetics and hypoglycemia. In: N elson L S, L ewin N A, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE, eds. Goldfrank ' s Toxicologic Emergencies. 9th ed. New York: McGraw-Hill ; 2011 : 714 - 727.
6. G erich J E. O ral hypoglycemic agents. N Engl J Med 1 989; 3 21: 1231 - 1245. (Pubitemid 19273033)
7. Das AK, Shah S. History of diabetes: from ants to analogs. J Assoc Physicians India 2011; 59(Suppl): 6- 7.
8. N agasawa H T, D eMaster E G, K won C H, F raser P S, S hirota F N. Structure vs. activity in the sulfonylurea-mediated disulfi ram-ethanol reaction. Alcohol 1985; 2 : 123 - 128. (Pubitemid 15119123)
9. Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS. Glipizide: A review of its pharmacological properties and therapeutic use. Drugs 1979; 18 : 329 - 353. (Pubitemid 10245409)
10. P rendergast B D. G lyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents. Clin Pharm 1984; 3: 473- 485. (Pubitemid 14030979)
11. Melander A. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: Brief overview. Diabetes 2004; 53(Suppl 3) : S151 - S155. (Pubitemid 39564537)
12. AHFS Drug Information. American Hospital Formulary Service Board of the American Society of Health System Pharmacists 1998; 68 : 2595 - 2597.
13. Hussain K, Mundi H, Aynsley-Green A, Champion M. A child presenting with disordered consciousness, hallucinations, screaming episodes and abdominal pain. Eur J Pediatr 2002; 161 : 127 - 129. (Pubitemid 34143513)
14. Matteucci MJ. One pill can kill: Assessing the potential for fatal poisonings in children. Pediatr Ann 2005; 34 : 964 - 968. (Pubitemid 41812777)
15. Little GL, Boniface KS. Are one or two dangerous? Sulfonylurea exposure in toddlers. J Emerg Med 2005; 28 : 305 - 310. (Pubitemid 40363915)
16. Glatstein M, Garcia-Bournissen F, Scolnik D, Koren G, Finkelstein Y. Hypoglycemia in a healthy toddler. Ther Drug Monit 2009; 31: 173 - 177.
17. Glatstein M, Garcia-Bournissen F, Scolnik D, Koren G. Sulfonylurea intoxication at a tertiary care paediatric hospital. Can J Clin Pharmacol 2010; 17 : E51 - 6.
18. Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber DA, Bronstein AC, Wruk KM. 2005 Annual Report of the American Association of Poison Control Centers ' national poisoning and exposure database. Clin Toxicol 2006; 44 : 803 - 932.
19. Bronstein AC, Spyker DA, Cantilena LR Jr., Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers ' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol 2011; 49 : 910 - 941.
20. Burge MR, Schmitz-Fiorentino K, Fischette C, Qualls CR, Schade DS. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 1998; 279 : 137 - 143. (Pubitemid 28068304)
21. Owen L, Ellis M, Shield J. Deliberate sulphonylurea poisoning mimicking hyperinsulinaemia of infancy. Arch Dis Child 2000; 82 : 392 - 393. (Pubitemid 30307770)
22. Vialettes B, Vague P. The clinical value of C-peptide assay. Diabetes Metab 1980; 6 : 225 - 229. (Pubitemid 11129843)
23. Lheureux PE, Zahir S, Penaloza A, Gris M. Bench-to bedside review: Antidotal treatment of sulphonylurea-induced hypoglycaemia with octreotide. Crit Care 2005; 9 : 543 - 549. (Pubitemid 43174460)
24. J ohnson S F, S chade D S, P eake G T. C hlorpropamide-induced hypoglycemia: successful treatment with diazoxide. Am J Med 1977; 63 : 799 - 804. (Pubitemid 8222946)
25. Graudins A, Linden CH, Ferm RP. Diagnosis and treatment of sulphonylurea-induced hyperinsulinaemic hypoglycemia. Am J Emerg Med 1997; 15 : 95 - 96. (Pubitemid 27044677)
26. Katz MD, Erstad BL. Octreotide, a new somatostain analogue. Clin Pharm 1989; 8 : 255 - 273.
27. D oyle M E, E gan J M. P harmacological agents that directly modulate insulin secretion. Pharmacol Rev 2003; 55 : 105 - 131.
28. Azkur D, Yoldas T, Toyran M, Kocabas CN. A pediatric case of anaphylaxis due to octreotide. Asian Pac J Allergy Immunol 2011; 29 : 361 - 363.
29. Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, Lamberts SW. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther 2005; 78: 69- 80. (Pubitemid 40956933)
30. Gregersen T, Gr ø nb æ k H, Wors ø e J, Schlageter V, Laurberg S, Krogh K. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. Scand J Gastroenterol 2011; 46 : 895 - 902.
31. Thompson CS, O ' Dorisio TM, Woltering EA. Calcium reverses octreotide inhibition of insulin and glucagon levels in patients with insulinoma and glucagonoma. Digestion 1996; 57(Suppl 1) : 62 - 68. (Pubitemid 26183925)
32. Howland MA. Octreotide. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE, eds. Goldfrank ' s toxicologic emergencies. 9th ed. New York: McGraw-Hill; 2011 : 734 - 737.
33. Kutz K, N ü esch E, Rosenthaler J. Pharmacokinetics of SMS 201 - 995 in healthy subjects. Scand J Gastroenterol Suppl 1986; 119: 65- 72. (Pubitemid 16057845)
34. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly. Growth Horm IGF Res 2005; 15 : 200 - 206. (Pubitemid 40754122)
35. McKeage K, Cheer S, Wagstaff AJ. Octreotide long-acting release (LAR): A review of its use in the management of acromegaly. Drugs 2003; 3 : 2473 - 2499. (Pubitemid 37392914)
36. Chanson P, Timsit J, Harris AG. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin Pharmacokinet 1993; 25 : 375 - 391. (Pubitemid 23327923)
37. Sakurai H, Dobbs R, Unger RH. Somatostatin-induced changes in insulin and glucagon secretion in normal and diabetic dogs. J Clin Invest 1974; 54 : 1395 - 1402.
38. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201 - 995: A very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 1982; 31 : 1133 - 1140. (Pubitemid 13243115)
39. Gul M, Cander B, Girisgin S, Ayan M, Kocak S, Unlu A. The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose. Adv Ther 2006; 23 : 878 - 884. (Pubitemid 46341046)
40. Gerich JE, Lorenzi M, Schneider V, Forsham PH. Effect of somatostatin on plasma glucose and insulin responses to glucagon and tolbutamide in man. J Clin Endocrinol Metab 1974; 39 : 1057 - 1060.
41. Boyle PJ, Justice K, Krentz AJ, Nagy RJ, Schade DS. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab 1993; 76 : 752 - 756. (Pubitemid 23086500)
42. K rentz A J, B oyle P J, M acdonald L M, S chade D S. O ctreotide: A longacting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 1994; 43: 24- 31. (Pubitemid 24047101)
43. Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, H ä ring HU. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care 2002; 25 : 2065 - 2073.
44. Phillips RE, Warrell DA, Looareesuwan S, Turner RC, Bloom SR, Quantrill D, Moore AR. Effectiveness of SMS 201 - 995, a synthetic, long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia. Lancet 1986; 1: 713- 716.
45. Lee PE, Meneilly GS. The effect of octreotide on glucose and insulin levels in a patient with type 2 diabetes on glibenclamide. Diabetes Metab 1999; 25 : 347 - 349.
46. Gardner-Roehnelt NM. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects. Clin J Oncol Nurs 2012; 16 : 56 - 64.
47. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofl and LJ. Octreotide. N Eng J Med 1996; 334 : 246 - 254. (Pubitemid 26030676)
48. Losa M, Mortini P, Giovanelli M. The role of somatostatin analogues in the treatment of hypophyseal adenomas. Minerva Endocrinol 2003; 28 : 39 - 51.
49. Le Quan Sang KH, Arnoux JB, Mamoune A, Saint-Martin C, Bellann é -Chantelot C, Valayannopoulos V, et al. Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol 2012; 166 : 333 - 339.
50. R ath S, B ar-Zeev N, A nderson K, F ahy R, R oseby R. O ctreotide in children with hypoglycaemia due to sulfonylurea ingestion. J Paediatr Child Health 2008; 44 : 383 - 384. (Pubitemid 351677495)
51. Kent DA, Main BA, Friesen MS. Use of octreotide in sulfonylurea poisoning in a child. J Toxicol Clin Toxicol 2003; 41 : 669 (abstract).
52. Mordel A, Sivilotti MLA, Old AC, Ferm RP. Octreotide for pediatric sulphonylurea poisoning. J Toxicol Clin Toxicol 1998; 36 : 437 (abstract).
53. Pelavin PI, Abramson E, Pon S, Vogiatzi MG. Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide. J Pediatr Endocrinol Metab 2009; 22 : 171 - 175.
54. Calello DP, Osterhoudt KC, Henretig FM, Perrone J. Octreotide for pediatric sulfonylurea overdose: Review of 5 cases. Clin Toxicol 2005; 43 : 671 (abstract).
55. Calello DP, Kelly A, Osterhoudt KC. Case fi les of the Medical Toxicology Fellowship Training Program at the Children's Hospital of Philadelphia: A pediatric exploratory sulfonylurea ingestion. J Med Toxicol 2006; 2 : 19 - 24.
56. Soderstrom J, Murray L, Daly FFS, Little M. Toxicology case of the month: oral hypoglycaemic overdose. Emerg Med J 2006; 23: 565- 567. (Pubitemid 44295267)
57. Fasano CJ, O ' Malley G, Dominici P, Aguilera E, Latta DR. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med 2008; 51 : 400 - 406. (Pubitemid 351400282)
58. McLaughlin SA, Crandall CS, McKinney PE. Octreotide: An antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med 2000; 36 : 133 - 138. (Pubitemid 30667018)
59. Fleseriu M, Skugor M, Chinnappa P, Siraj ES. Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide. Endocr Pract 2006; 12 : 635 - 640.
60. A dabala M, J haveri K D, G itman M. S evere hyperkalaemia resulting from octreotide use in a haemodialysis patient. Nephrol Dial Transplant 2010; 25 : 3439 - 3442.
61. Hung O, Eng J, Ho J, Aks S, Howland M, Erickson T, Hoffman R. Octreotide as an antidote for refractory sulfonylurea hypoglycemia. J Toxicol Clin Toxicol 1997; 35 : 540 - 541 (abstract).
62. Vallurupalli S. Safety of subcutaneous octreotide in patients with sulfonylurea-induced hypoglycemia and congestive heart failure. Ann Pharmacother 2010; 44 : 387 - 390.
63. Green RS, Palatnick W. Effectiveness of octreotide in a case of refractory sulfonylurea-induced hypoglycemia. J Emerg Med 2003; 25 : 283 - 287. (Pubitemid 37324665)
64. Braatvedt GD. Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes. N Z Med J 1997; 110: 189- 190. (Pubitemid 27211804)
65. Bui L, Adler D, Keller KH. Prolonged octreotide infusion to treat glyburide-induced hypoglycemia. J Toxicol Clin Toxicol 2000; 38: 576 (abstract).
66. C arr R, Z ed P J. O ctreotide for sulfonylurea-induced hypoglycemia following overdose. Ann Pharmacother 2002; 36 : 1727 - 1732.
67. Crawford BAL, Perera C. Octreotide treatment for sulfonylureainduced hypoglycemia. Med J Aust 2004; 180: 540- 541.
68. Krentz AJ, Boyle PJ, Justice KM, Wright AD, Schade DS. Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide. Diabetes Care 1993; 16 : 184 - 186. (Pubitemid 23013843)
69. Nzerue CM, Thomas J, Volcy J, Edeki T. Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure. Int J Artif Organs 2003; 26: 86- 89. (Pubitemid 36896254)
70. Gonzalez RR, Zweig S, Rao J, Block R, Greene LW. Octreotide therapy for recurrent refractory hypoglycemia due to sulfonylurea in diabetes-related kidney failure. Endocr Pract 2007; 13 : 417 - 423.
71. H anchard B, B oulouffe C, V anpee D. S ulfonylurea-induced hypoglycaemia: use of octreotide. Acta Clin Belg 2009; 64 : 56 - 58.
72. K elesidis T, C anseco E. Q uinolone-induced hypoglycemia: A lifethreatening but potentially reversible side effect. Am J Med 2010; 123 : E5 - 6
73. Hung WP, Wang JN, Chang HK, Wu JM. Octreotide therapy in two children with intractable postoperative chylothorax. Int J Cardiol 2011; 146 : E63 - 65